ArticleMalaria journal2026
Control of pyrethroid-resistant Anopheles gambiae s.l. with Sovrenta® 15WP, a new isoxazoline insecticide for indoor residual spraying.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAn expanded portfolio of more effective WHO-prequalified insecticides for indoor residual sparing (IRS) is needed to provide additional options to disease control programmes and enhance their capacity to efficiently apply IRS rotations for managing vector resistance to insecticides. We investigated the efficacy and residual activity of Sovrenta® 15WP, a wettable powder formulation of the newly discovered isoxazoline insecticide isocycloseram, (active ingredient trademarked as PLINAZOLIN® technology) for IRS in laboratory bioassays and experimental hut studies.
methodsSovrenta® 15WP, was evaluated under laboratory conditions for 12 months at the dose of 120 mg a.i./m
conclusionSovrenta® 15WP provided extended control of pyrethroid-resistant malaria vectors when applied for IRS on local wall substrates. The insecticide presents a new effective IRS option for achieving improved malaria control and managing insecticide resistance through the rotation of IRS insecticides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.